Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)
Michele Marchioni(University of Chieti-Pescara), Maria Carmen Mir(Fundación Instituto Valenciano de Oncología), Vital Hevia(Hospital Universitario Ramón y Cajal), Aaron Bradshaw(University of California San Diego), Tobias Klatte(Helios Hospital Bad Saarow), Francesco Porpiglia(University of Turin), Selçuk Erdem(European Association of Urology), Estefanía Linares(Hospital Universitario La Paz), Andrea Minervini(Azienda Ospedaliero-Universitaria Careggi), Riccardo Campi(University of Florence), Riccardo Autorino(Rush University Medical Center), Thomas Amiel(Technical University of Munich), Maximilian C. Kriegmair(University Medical Centre Mannheim), Georgi Guruli(VCU Massey Comprehensive Cancer Center), Enrico Ceccucci(University of Turin), Siska Van Bruwaene(AZ Groeninge), Mireía Musquera(Surgical Specialties (Canada)), Alessandro Antonelli(University of Verona), Nicola Pavan(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Francesco Claps(University of Trieste), Alessandro Veccia(University of Verona), Maarten Albersen, Ithaar Derweesh(Rush University Medical Center), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Mathias Heck(Technical University of Munich), Carlotta Palumbo(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mauricio D’Anna(Hospital Clínic de Barcelona), Eduard Roussel
Cited by 34
Related Papers
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Urology practice during the COVID-19 pandemic
|Minerva Urologica e Nefrologica|2020|256